Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib

July 19, 2017
Dirk Schadendorf, MD

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients with&nbsp;<em>BRAF V600E/K</em>-mutant metastatic melanoma who received dabrafenib (Tafinlar) plus trametinib (Mekinist) in the randomized phase III COMBI-v study.

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients withBRAF V600E/K